MCID: LKM062
MIFTS: 69

Leukemia, Acute Lymphoblastic

Categories: Rare diseases, Cancer diseases, Genetic diseases, Immune diseases, Blood diseases

Aliases & Classifications for Leukemia, Acute Lymphoblastic

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Name: Leukemia, Acute Lymphoblastic 57 75 13 13 13 13 38
Acute Lymphoblastic Leukemia 38 76 53 29 6
Leukemia, Acute Lymphoblastic, Susceptibility to 29 13 6
All 57 53 75
Leukemia, T-Cell Acute Lymphoblastic 13 40
Acute Lymphocytic Leukemia 53 73
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 73
Leukemia, Acute Lymphocytic, Susceptibility to, 1 57
Precursor Cell Lymphoblastic Leukemia Lymphoma 73
Leukemia Acute Lymphoblastic B-Hyperdiploid 75
Childhood Acute Lymphoblastic Leukemia 75
Leukemia, Acute, Lymphoblastic, T-Cell 40
Leukemia, Acute T-Cell Lymphoblastic 13
Leukemia B-Cell Acute Lymphoblastic 75
Leukemia T-Cell Acute Lymphoblastic 75
Leukemia, Acute Lymphoblastic, 3 75
Leukemia, Lymphocytic, Acute, L1 73
Leukemia Acute Lymphoblastic 1 75
Leukemia, Acute, Lymphoblastic 40
Leukemia, Acute Lymphocytic 1 57
Leukemia Acute Lymphocytic 1 75
Lymphoblastic Leukemia Acute 55
Leukemia, Acute Lymphocytic 13
Leukemia Acute Lymphocytic 75
All3 75
All1 75

Characteristics:

HPO:

32
leukemia, acute lymphoblastic:
Inheritance polygenic inheritance


Classifications:



Summaries for Leukemia, Acute Lymphoblastic

NIH Rare Diseases : 53 Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males). Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin. ALL is typically caused by random, non-inherited changes in the DNA of immature lymphocytes called lymphoblasts. However, some people may inherit a genetic susceptibility to developing ALL. The risk to develop ALL may also be increased by past treatment for cancer, and by having certain genetic conditions or syndromes. Having one or more risk factors does not mean that a person definitely will develop ALL. Treatment of ALL depends on the person's age, how advanced the cancer is, and whether certain genetic changes are found in cancer cells. Treatment options may involve systemic and/or intrathecal chemotherapy, radiation therapy, targeted therapy, and/or a stem cell transplant. Biologic therapy and chimeric antigen receptor (CAR) T-cell therapy are currently being studied as treatment options and may be used when other therapies are not working. The chance of recovery also depends on many factors. With treatment, about 98% of children with ALL go into remission, and 85% of those with first-time ALL are expected have no long-term complications. The chance of recovery for adults is not as high, as 20-40% of adults are cured with current treatments.

MalaCards based summary : Leukemia, Acute Lymphoblastic, also known as acute lymphoblastic leukemia, is related to leukemia, acute lymphoblastic 3 and acute leukemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia, Acute Lymphoblastic is ETV6 (ETS Variant 6), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Arranon and Blincyto have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotype is acute lymphoblastic leukemia.

OMIM : 57 Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). (613065)

UniProtKB/Swiss-Prot : 75 Leukemia, acute lymphoblastic: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes. Leukemia, acute lymphoblastic, 3: A subtype of acute leukemia, a cancer of the white blood cells. Acute lymphoblastic anemia is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

Wikipedia : 76 Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...

Related Diseases for Leukemia, Acute Lymphoblastic

Diseases in the Lymphoblastic Leukemia family:

Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic 2
Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 3 34.9 ETV6 FLT3 PAX5
2 acute leukemia 30.7 ETV6 FLT3 PAX5
3 leukemia, acute myeloid 29.1 ETV6 FLT3 MIR155 MIR199B MIR21 MIR210
4 acute lymphoblastic leukemia, childhood 12.5
5 b-cell childhood acute lymphoblastic leukemia 12.5
6 precursor t-cell acute lymphoblastic leukemia 12.3
7 leukemia, acute lymphoblastic 2 12.3
8 acute lymphoblastic leukemia congenital sporadic aniridia 12.1
9 acute t cell leukemia 11.8
10 lymphoblastic leukemia, acute, with lymphomatous features 11.5
11 acute lymphocytic leukemia 11.1
12 lymphoid leukemia 11.1 ETV6 FLT3 GNB1
13 ovarian serous carcinoma 10.9 MIR21 MIR23B MIR27A
14 neutrophilia, hereditary 10.9 FLT3 MIR223
15 mn1 10.9 ETV6 FLT3
16 muscular dystrophy, limb-girdle, type 2a 10.9 MIR221 MIR222 MIR223
17 lymphoma, hodgkin, classic 10.9 MIR155 MIR21 PAX5
18 leiomyoma, uterine 10.9 MIR203A MIR21 MIRLET7C
19 polymyositis 10.9 MIR155 MIR21 MIR210 MIR222
20 nonalcoholic fatty liver disease 10.9 MIR203A MIR22 MIR27A MIRLET7C
21 leukemia, chronic myeloid 10.8 ETV6 FLT3 MIR203A MIR223
22 kidney cancer 10.8 MIR21 MIR210 MIR27A
23 diffuse large b-cell lymphoma 10.8 MIR155 MIR21 MIR210 MIR221
24 pancreatic ductal adenocarcinoma 10.8 MIR155 MIR203A MIR21 MIR221 MIR223
25 inclusion body myositis 10.8 MIR155 MIR21 MIR221 MIR222 MIR223
26 facioscapulohumeral muscular dystrophy 1 10.8 MIR155 MIR199B MIR21 MIR221 MIR222
27 thyroid cancer, nonmedullary, 1 10.7 MIR155 MIR199B MIR21 MIR221 MIR222
28 squamous cell carcinoma, head and neck 10.7 MIR155 MIR21 MIR210 MIR22 MIR221
29 acute promyelocytic leukemia 10.7 FLT3 MIR210 MIR221 MIR223 MIRLET7C
30 ulcerative colitis 10.7 MIR203A MIR21 MIR23B
31 leukemia, chronic lymphocytic 10.7 MIR155 MIR21 MIR221 MIR223 MIR23B PAX5
32 glioblastoma multiforme 10.7 MIR155 MIR21 MIR210 MIR221
33 bone marrow cancer 10.6 ETV6 FLT3 MIR155
34 muscular dystrophy, duchenne type 10.6 MIR155 MIR199B MIR210 MIR22 MIR221 MIR222
35 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.6 ETV6 FLT3
36 dermatomyositis 10.6 MIR199B MIR21 MIR210 MIR221 MIR222 MIR223
37 glioma 10.6 MIR21 MIR210 MIR221 MIR222
38 bladder cancer 10.6 MIR203A MIR21 MIR221 MIR222 MIR223 MIR23B
39 melanoma 10.5 MIR199B MIR210 MIR221 MIR222 MIR23B MIR27A
40 gastric cancer 10.5 MIR203A MIR21 MIR221 MIR222 MIR223 MIR27A
41 lymphoblastic leukemia 10.5
42 leukemia 10.4
43 oral squamous cell carcinoma 10.4 MIR155 MIR199B MIR203A MIR21 MIR221 MIR223
44 ovarian cancer 10.4 MIR155 MIR21 MIR210 MIR221 MIR222 MIR223
45 pancreatic cancer 10.3 MIR155 MIR203A MIR21 MIR210 MIR221 MIR222
46 glioblastoma 10.0 MIR21 MIR221 MIR222 MIR23B
47 lung cancer 10.0 MIR155 MIR199B MIR203A MIR21 MIR210 MIR22
48 breast cancer 10.0 MIR152 MIR155 MIR199B MIR203A MIR21 MIR210
49 prostate cancer 9.9 MIR199B MIR203A MIR21 MIR210 MIR22 MIR221
50 hepatocellular carcinoma 9.8 MIR152 MIR155 MIR199B MIR203A MIR21 MIR22

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:



Diseases related to Leukemia, Acute Lymphoblastic

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

Clinical features from OMIM:

613065

Human phenotypes related to Leukemia, Acute Lymphoblastic:

32
# Description HPO Frequency HPO Source Accession
1 acute lymphoblastic leukemia 32 HP:0006721

UMLS symptoms related to Leukemia, Acute Lymphoblastic:


angina pectoris, chest pain, edema

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

FDA approved drugs:

(show all 7)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
2
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
3
Clolar 18 49 CLOFARABINE Genzyme December, 2004
4
Erwinaze 18 49 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
5
Iclusig 18 49 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
6
Marqibo 18 49 VINCRISTINE SULFATE Talon Therapeutics August 2012
7
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 619)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
5
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
6
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
7
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
8
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
10
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
13
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 174722-31-7 10201696
14
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
15
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130167-69-0
16
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 4291-63-8 20279
17
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
18
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
19
Teniposide Approved Phase 4,Phase 3,Phase 2,Not Applicable 29767-20-2 34698
20
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
21
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
22
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 3778-73-2 3690
23
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
24
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
25
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
26
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
27
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
28
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
29
Posaconazole Approved, Investigational, Vet_approved Phase 4,Not Applicable 171228-49-2 147912
30
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
31
Methylphenidate Approved, Investigational Phase 4,Not Applicable 113-45-1 4158
32
Oprelvekin Approved, Investigational Phase 4 145941-26-0
33
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
34
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
35
Nicotine Approved Phase 4 54-11-5 942 89594
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
37
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
38
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
39
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
40
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
41
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
42
Butyric Acid Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 107-92-6 264
43
Treosulfan Investigational Phase 4,Phase 3,Phase 2,Phase 1 299-75-2 9296
44
Lactitol Investigational Phase 4,Phase 2,Phase 1 585-86-4 3871
45 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1771)
# Name Status NCT ID Phase Drugs
1 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
2 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
3 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
4 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
5 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
6 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
7 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
8 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
9 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
10 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
11 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
12 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
13 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
14 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
15 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
16 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
17 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
18 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
19 Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
20 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
21 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
22 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
23 Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL Completed NCT02314273 Phase 4 rhIL-11
24 The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
25 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
26 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
27 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
28 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
29 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
30 Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
31 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Recruiting NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
32 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Recruiting NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
33 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
34 Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid Recruiting NCT01906671 Phase 4 Xaluprine;Puri-Nethol
35 PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
36 Vaccinating Children After Chemotherapy Recruiting NCT02447718 Phase 4
37 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
38 Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Recruiting NCT02036489 Phase 4 Vincristine;Daunorubicin;Prednisone;L-asparaginase;Ciclophosphamide;Metotrexate;ARA-C;Hidrocortisone;Mercaptopurine;VP-16;Dexametasone
39 ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
40 A Clinical Trial of Decitabine in Relapse and Refractory T-lymphoblastic Lymphoma Recruiting NCT03558412 Phase 4 Decitabine
41 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Active, not recruiting NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
42 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
43 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
44 ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
45 Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL Terminated NCT00299234 Phase 4 Atomoxetine
46 Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia Unknown status NCT02072785 Phase 3 Vincristine Sulfate Liposome;Vincristine Sulfate
47 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00103285 Phase 3 doxorubicin hydrochloride;cytarabine;dexamethasone;pegaspargase;methotrexate;leucovorin calcium;mercaptopurine;cyclophosphamide;thioguanine;vincristine sulfate
48 Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt Unknown status NCT00199108 Phase 2, Phase 3 Depocyt;Dexamethasone
49 High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) Unknown status NCT00131027 Phase 3 Cyclophosphamide;Daunorubicin;Vincristine;Prednisolone;L-asparaginase;Cytarabine;Etoposide;Dexamethasone;Methotrexate;Mercaptopurine;Doxorubicin;Methotrexate
50 Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia Unknown status NCT00003437 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisolone;thioguanine;vincristine sulfate

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Lymphoblastic cell therapies at LifeMap Discovery.

Genetic Tests for Leukemia, Acute Lymphoblastic

Genetic tests related to Leukemia, Acute Lymphoblastic:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to 29
2 Acute Lymphoblastic Leukemia 29

Anatomical Context for Leukemia, Acute Lymphoblastic

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic:

41
T Cells, B Cells, Bone, Bone Marrow, Myeloid, Liver, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Lymphoblastic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Acute Lymphoblastic

Articles related to Leukemia, Acute Lymphoblastic:

(show top 50) (show all 3627)
# Title Authors Year
1
Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia. ( 28853218 )
2018
2
Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. ( 29360413 )
2018
3
Acute Lymphoblastic Leukemia Presenting as Fanconi Syndrome. ( 29515412 )
2018
4
Immunosuppressive monocytes (CD14<sup>+</sup>/HLA-DR<sup>low/-</sup>) increase in childhood precursor B-cell acute lymphoblastic leukemia after induction chemotherapy. ( 29429058 )
2018
5
Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism. ( 29977016 )
2018
6
The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK/ERK signaling pathway. ( 29330049 )
2018
7
Anti-E Detected in a 7-Month-Old Infant with Acute Lymphoblastic Leukemia after Transfusion. ( 29945333 )
2018
8
Long non-coding RNA PAX8-AS1 polymorphisms increase the risk of childhood acute lymphoblastic leukemia. ( 29435279 )
2018
9
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. ( 29954814 )
2018
10
<i>PDGFRB</i> mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. ( 29434033 )
2018
11
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. ( 29090524 )
2018
12
Erratum: Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]. ( 29443320 )
2018
13
Study of NOTCH1 and FBXW7 Mutations and Its Prognostic Significance in South Indian T-Cell Acute Lymphoblastic Leukemia. ( 29200162 )
2018
14
Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia. ( 29954929 )
2018
15
A rare e14a3 BCR/ABL fusion transcript in acute lymphoblastic leukemia patient treated with CAR-modified T-cell therapy. ( 29434963 )
2018
16
Combination of Blinatumomab and Vincristine Sulfate Liposome Injection for Treatment of Relapsed Philadelphia Chromosome Positive B-cell Acute Lymphoblastic Leukemia. ( 29953129 )
2018
17
Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia. ( 29967774 )
2018
18
Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate. ( 29424258 )
2018
19
Extranodal histiocytic sarcoma in a child with acute lymphoblastic leukemia: Cytomorphological features of a rare entity with brief review of literature. ( 29676378 )
2018
20
Successful Combination Therapy of Liposomal Amphotericin B and Caspofungin for Disseminated Fusariosis in a Pediatric Patient with Acute Lymphoblastic Leukemia. ( 29438132 )
2018
21
Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels. ( 29278703 )
2018
22
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia &amp;amp; lymphoma study. ( 29728694 )
2018
23
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. ( 29047158 )
2018
24
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. ( 29949919 )
2018
25
Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL). ( 29437555 )
2018
26
A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing. ( 29954933 )
2018
27
Living on a farm, contact with farm animals and pets, and childhood acute lymphoblastic leukemia: pooled and meta-analyses from the Childhood Leukemia International Consortium. ( 29663688 )
2018
28
Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. ( 29970035 )
2018
29
Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium. ( 29761423 )
2018
30
Recent Developments in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia. ( 29442287 )
2018
31
Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia. ( 29967378 )
2018
32
Nephrogenic diabetes insipidus in initial stage of acute lymphoblastic leukemia and relapse after haploidentical hematopoietic stem-cell transplantation: A case report. ( 29901649 )
2018
33
A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia. ( 29424254 )
2018
34
Brain morphology and information processing at the completion of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. ( 29969366 )
2018
35
Body composition in long-term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity. ( 29231963 )
2018
36
A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. ( 29922939 )
2018
37
Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults. ( 29418064 )
2018
38
Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. ( 29449437 )
2018
39
Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. ( 29943905 )
2018
40
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. ( 29450465 )
2018
41
Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation canA improve clinical outcomes. ( 29942002 )
2018
42
Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia. ( 29948644 )
2018
43
Acute lymphoblastic leukemia in a male with Simpson-Golabi-Behmel syndrome. ( 29737011 )
2018
44
Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. ( 28971501 )
2018
45
In vitro combinatorial anti-proliferative and immunosuppressive effects of Brucea javanica extract with CX-4945 and imatinib in human T-cell acute lymphoblastic leukemia cells. ( 29966986 )
2018
46
Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice. ( 29441205 )
2018
47
A strategy for the clinical remission of acute lymphoblastic leukemia elicited by treatment of I^-thalassemia major: A case report. ( 29435306 )
2018
48
A rare variant of t(17;19) in a case of Philadelphia positive adult acute lymphoblastic leukemia presenting with disseminated intravascular coagulation. ( 29662872 )
2018
49
Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia. ( 29966470 )
2018
50
Comparison of target volume and clinical effects of four radiotherapy plans for acute lymphoblastic leukemia prior to hematopoietic stem cell transplantation. ( 29956788 )
2018

Variations for Leukemia, Acute Lymphoblastic

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

75
# Symbol AA change Variation ID SNP ID
1 PAX5 p.Gly183Ser VAR_070682 rs398123063

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

6
(show all 21)
# Gene Variation Type Significance SNP ID Assembly Location
1 NBN NM_002485.4(NBN): c.511A> G (p.Ile171Val) single nucleotide variant risk factor rs61754966 GRCh37 Chromosome 8, 90990521: 90990521
2 NBN NM_002485.4(NBN): c.511A> G (p.Ile171Val) single nucleotide variant risk factor rs61754966 GRCh38 Chromosome 8, 89978293: 89978293
3 FLT3 NM_004119.2(FLT3): c.2504A> T (p.Asp835Val) single nucleotide variant Pathogenic rs121909646 GRCh37 Chromosome 13, 28592641: 28592641
4 FLT3 NM_004119.2(FLT3): c.2504A> T (p.Asp835Val) single nucleotide variant Pathogenic rs121909646 GRCh38 Chromosome 13, 28018504: 28018504
5 FLT3 NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr) single nucleotide variant Pathogenic rs121913488 GRCh37 Chromosome 13, 28592642: 28592642
6 FLT3 NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr) single nucleotide variant Pathogenic rs121913488 GRCh38 Chromosome 13, 28018505: 28018505
7 FLT3 NM_004119.2(FLT3): c.1777_1779delGAT (p.Asp593del) deletion Pathogenic rs587776834 GRCh38 Chromosome 13, 28034140: 28034142
8 FLT3 NM_004119.2(FLT3): c.1777_1779delGAT (p.Asp593del) deletion Pathogenic rs587776834 GRCh37 Chromosome 13, 28608277: 28608279
9 NBN NM_002485.4(NBN): c.2140C> T (p.Arg714Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730881864 GRCh38 Chromosome 8, 89943297: 89943297
10 NBN NM_002485.4(NBN): c.2140C> T (p.Arg714Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730881864 GRCh37 Chromosome 8, 90955525: 90955525
11 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh37 Chromosome 12, 12038855: 12038859
12 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh38 Chromosome 12, 11885921: 11885925
13 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh37 Chromosome 12, 12037415: 12037415
14 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh38 Chromosome 12, 11884481: 11884481
15 ACTB NP_001092.1(ACTB): p.Val209Leu protein only Pathogenic
16 GNB1 NM_002074.4(GNB1): c.239T> A (p.Ile80Asn) single nucleotide variant Pathogenic rs752746786 GRCh37 Chromosome 1, 1737942: 1737942
17 GNB1 NM_002074.4(GNB1): c.239T> A (p.Ile80Asn) single nucleotide variant Pathogenic rs752746786 GRCh38 Chromosome 1, 1806503: 1806503
18 GNB1 NM_002074.4(GNB1): c.227A> G (p.Asp76Gly) single nucleotide variant Pathogenic rs869312821 GRCh38 Chromosome 1, 1806515: 1806515
19 GNB1 NM_002074.4(GNB1): c.227A> G (p.Asp76Gly) single nucleotide variant Pathogenic rs869312821 GRCh37 Chromosome 1, 1737954: 1737954
20 NBN NM_002485.4(NBN): c.156_157delTT (p.Ser53Cysfs) deletion Pathogenic/Likely pathogenic rs767454740 GRCh38 Chromosome 8, 89982736: 89982737
21 NBN NM_002485.4(NBN): c.156_157delTT (p.Ser53Cysfs) deletion Pathogenic/Likely pathogenic rs767454740 GRCh37 Chromosome 8, 90994964: 90994965

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

7 (show top 50) (show all 2943)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13316 1 1 117600000 Loss Acute lymphoblastic leukemia
2 13371 17 1 22200000 Deletion TP53 Acute lymphoblastic leukemia
3 13410 1 1 2300000 Copy number Acute lymphoblastic leukemia
4 13773 1 1 35400000 Duplication Acute lymphoblastic leukemia
5 13788 1 1 40300000 Duplication Acute lymphoblastic leukemia
6 13790 1 1 46500000 Gain Acute lymphoblastic leukemia
7 13836 12 10000000 12600000 Deletion ETV6 Acute lymphoblastic leukemia
8 13906 1 100818677 103024856 Loss DPH5 Acute lymphoblastic leukemia
9 13907 1 100818677 103024856 Loss EXTL2 Acute lymphoblastic leukemia
10 13908 1 100818677 103024856 Loss OLFM3 Acute lymphoblastic leukemia
11 13909 1 100818677 103024856 Loss S1PR1 Acute lymphoblastic leukemia
12 13910 1 100818677 103024856 Loss SLC30A7 Acute lymphoblastic leukemia
13 13911 1 100818677 103024856 Loss VCAM1 Acute lymphoblastic leukemia
14 13991 1 102370195 102561809 Deletion Acute lymphoblastic leukemia
15 14292 1 106673274 107678605 Loss NTNG1 Acute lymphoblastic leukemia
16 14293 1 106673274 107678605 Loss PRMT6 Acute lymphoblastic leukemia
17 14369 1 107716342 144004701 Loss ADAM30 Acute lymphoblastic leukemia
18 14370 1 107716342 144004701 Loss ADORA3 Acute lymphoblastic leukemia
19 14371 1 107716342 144004701 Loss AFARP1 Acute lymphoblastic leukemia
20 14372 1 107716342 144004701 Loss AHCYL1 Acute lymphoblastic leukemia
21 14373 1 107716342 144004701 Loss AKNAD1 Acute lymphoblastic leukemia
22 14374 1 107716342 144004701 Loss ALX3 Acute lymphoblastic leukemia
23 14375 1 107716342 144004701 Loss AMIGO1 Acute lymphoblastic leukemia
24 14376 1 107716342 144004701 Loss AMPD1 Acute lymphoblastic leukemia
25 14377 1 107716342 144004701 Loss AMPD2 Acute lymphoblastic leukemia
26 14378 1 107716342 144004701 Loss AP4B1 Acute lymphoblastic leukemia
27 14379 1 107716342 144004701 Loss ATP1A1 Acute lymphoblastic leukemia
28 14380 1 107716342 144004701 Loss ATP5F1 Acute lymphoblastic leukemia
29 14381 1 107716342 144004701 Loss ATXN7L2 Acute lymphoblastic leukemia
30 14382 1 107716342 144004701 Loss BCAS2 Acute lymphoblastic leukemia
31 14383 1 107716342 144004701 Loss BCL2L15 Acute lymphoblastic leukemia
32 14384 1 107716342 144004701 Loss C1orf103 Acute lymphoblastic leukemia
33 14385 1 107716342 144004701 Loss C1orf152 Acute lymphoblastic leukemia
34 14386 1 107716342 144004701 Loss C1orf161 Acute lymphoblastic leukemia
35 14387 1 107716342 144004701 Loss C1orf162 Acute lymphoblastic leukemia
36 14388 1 107716342 144004701 Loss C1orf183 Acute lymphoblastic leukemia
37 15383 1 115048600 115061038 Copy number NRAS Acute lymphoblastic leukemia
38 15429 1 115400000 222100000 Gain Acute lymphoblastic leukemia
39 15832 1 119869201 120436800 Loss HMGCS2 Acute lymphoblastic leukemia
40 15833 1 119869201 120436800 Loss NBPF7 Acute lymphoblastic leukemia
41 15834 1 119869201 120436800 Loss NOTCH2 Acute lymphoblastic leukemia
42 15835 1 119869201 120436800 Loss PHGDH Acute lymphoblastic leukemia
43 15836 1 119869201 120436800 Loss REG4 Acute lymphoblastic leukemia
44 15837 1 119869201 120436800 Loss ZNF697 Acute lymphoblastic leukemia
45 15979 1 120700000 169100000 Loss CREG1 Acute lymphoblastic leukemia
46 16426 1 124300000 247249719 Deletion Acute lymphoblastic leukemia
47 16427 1 124300000 247249719 Duplication Acute lymphoblastic leukemia
48 16474 1 125000000 249250621 Copy number Acute lymphoblastic leukemia
49 16502 1 12600000 16100000 Deletion Acute lymphoblastic leukemia
50 16592 1 128000000 185104377 Copy number Acute lymphoblastic leukemia

Expression for Leukemia, Acute Lymphoblastic

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic.

Pathways for Leukemia, Acute Lymphoblastic

GO Terms for Leukemia, Acute Lymphoblastic

Cellular components related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.44 ACTB MIR152 MIR155 MIR199B MIR21 MIR210

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.84 MIR199B MIR21 MIR221 MIR222
2 positive regulation of angiogenesis GO:0045766 9.82 MIR199B MIR21 MIR210
3 negative regulation of inflammatory response GO:0050728 9.77 MIR155 MIR221 MIR222
4 positive regulation of inflammatory response GO:0050729 9.76 MIR155 MIR21 MIR22
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.72 FLT3 MIR21 MIR221 MIR222 MIR27A
6 positive regulation of epithelial to mesenchymal transition GO:0010718 9.7 MIR21 MIR221 MIR222
7 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.69 MIR155 MIR22 MIR221
8 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 MIR21 MIR221 MIR222
9 positive regulation of cardiac muscle cell proliferation GO:0060045 9.65 MIR199B MIR222 MIR23B
10 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.64 MIR155 MIR222
11 positive regulation of activated T cell proliferation GO:0042104 9.63 MIR155 MIR21
12 positive regulation of cardiac muscle hypertrophy GO:0010613 9.63 MIR155 MIR21
13 positive regulation of vascular endothelial cell proliferation GO:1905564 9.62 MIR21 MIR27A
14 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.62 MIR21 MIR221
15 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.61 MIR21 MIR223
16 positive regulation of endothelial cell differentiation GO:0045603 9.61 MIR199B MIR21
17 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.59 MIR221 MIR222
18 positive regulation of axon regeneration GO:0048680 9.58 MIR221 MIR222
19 negative regulation by host of viral genome replication GO:0044828 9.57